MXPA05005045A - Vacuna de polisacarido para infecciones estafilococicas. - Google Patents

Vacuna de polisacarido para infecciones estafilococicas.

Info

Publication number
MXPA05005045A
MXPA05005045A MXPA05005045A MXPA05005045A MXPA05005045A MX PA05005045 A MXPA05005045 A MX PA05005045A MX PA05005045 A MXPA05005045 A MX PA05005045A MX PA05005045 A MXPA05005045 A MX PA05005045A MX PA05005045 A MXPA05005045 A MX PA05005045A
Authority
MX
Mexico
Prior art keywords
polysaccharide
further characterized
daltons
isolated
composition according
Prior art date
Application number
MXPA05005045A
Other languages
English (en)
Spanish (es)
Inventor
Tomas Maira-Litran
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of MXPA05005045A publication Critical patent/MXPA05005045A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MXPA05005045A 2002-11-12 2003-11-12 Vacuna de polisacarido para infecciones estafilococicas. MXPA05005045A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42542502P 2002-11-12 2002-11-12
PCT/US2003/036358 WO2004043405A2 (en) 2002-11-12 2003-11-12 Polysaccharide vaccine for staphylococcal infections

Publications (1)

Publication Number Publication Date
MXPA05005045A true MXPA05005045A (es) 2005-07-01

Family

ID=32312989

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05005045A MXPA05005045A (es) 2002-11-12 2003-11-12 Vacuna de polisacarido para infecciones estafilococicas.

Country Status (18)

Country Link
US (1) US10919956B2 (enExample)
EP (1) EP1565478B1 (enExample)
JP (5) JP5814494B2 (enExample)
KR (1) KR101062525B1 (enExample)
CN (1) CN100351260C (enExample)
AU (1) AU2003295520B8 (enExample)
BR (1) BRPI0316018B8 (enExample)
CA (1) CA2501077C (enExample)
DK (1) DK1565478T3 (enExample)
ES (1) ES2648046T3 (enExample)
IL (3) IL167532A (enExample)
MX (1) MXPA05005045A (enExample)
NO (1) NO341730B1 (enExample)
NZ (1) NZ539153A (enExample)
PL (1) PL229487B1 (enExample)
PT (1) PT1565478T (enExample)
WO (1) WO2004043405A2 (enExample)
ZA (1) ZA200502607B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994015117A1 (fr) 1992-12-28 1994-07-07 Yoshiki Industrial Co., Ltd. Levier presentant un point de support fixe, un point de force oscillant et un point d'application oscillant, et machine-outil utilisant ce levier
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
AU2003290867A1 (en) * 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
WO2004043405A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
PL1745075T3 (pl) 2004-04-21 2013-09-30 Brigham & Womens Hospital Inc Peptydy wiążące poli-N-acetyloglukozaminę (PNAG/DPNAG) i sposoby ich zastosowania
ES2730275T3 (es) 2004-09-22 2019-11-11 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
BRPI0516974A (pt) * 2004-10-21 2008-09-30 Wyeth Corp composição imunogênica compreendendo um polipeptìdeo; um método para induzir uma resposta imune contra staphylococcus epidermidis; um método para induzir uma resposta imune contra staphylococcus aureus; um método para a detecção e/ou identificação de staphylococcus epidermidis; um método para a detecção e/ou identificação de anticorpos para staphylococcus epidermidis
NZ570805A (en) 2006-03-30 2011-10-28 Glaxosmithkline Biolog Sa Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus
AR060187A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
DK2027155T3 (en) 2006-06-06 2016-05-09 Crucell Holland Bv HUMAN BINDING MOLECULES with killer activity against staphylococci and uses thereof
US7960518B2 (en) 2006-06-06 2011-06-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
CN102159540B (zh) * 2008-07-21 2015-08-12 布赖汉姆妇女医院 与合成的β-1,6葡糖胺寡糖相关的方法和组合物
US20110262477A1 (en) 2008-10-06 2011-10-27 University Of Chicago Compositions and Methods Related to Bacterial EAP, EMP, and/or ADSA Proteins
HRP20160274T1 (hr) 2009-04-03 2016-04-08 University Of Chicago Pripravci i metode vezane za varijante proteina a (spa)
AU2010264538B2 (en) 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
WO2011041003A2 (en) 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
US8974799B2 (en) 2009-09-30 2015-03-10 Novartis Ag Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
PT2493498T (pt) 2009-10-30 2017-05-24 Glaxosmithkline Biologicals Sa Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8
PL2547361T3 (pl) 2010-03-17 2021-02-22 Socpra - Sciences Et Génie, S.E.C. Bakteryjne składniki szczepionek pochodzące ze staphylococcus aureus i ich zastosowania
EP2555794A4 (en) 2010-04-05 2014-01-15 Univ Chicago COMPOSITIONS AND METHODS RELATING TO PROTEIN A (SPA) ANTIBODIES AS IMMUNE REACTION AMPLIFIERS
CA2797052A1 (en) * 2010-04-23 2011-10-27 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for staphyloccocus vaccine
AU2011274367B2 (en) 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 感染防御ブドウ球菌抗原が関与する方法および組成物
WO2013162746A1 (en) 2012-04-26 2013-10-31 University Of Chicago Staphylococcal coagulase antigens and methods of their use
KR20150024315A (ko) * 2012-05-07 2015-03-06 재단법인 목암생명공학연구소 포도상구균 감염 예방용 백신 조성물
ES2826000T3 (es) * 2012-05-30 2021-05-17 Brigham & Womens Hospital Inc Composiciones de polisacárido y métodos de uso
WO2015183041A1 (ko) * 2014-05-29 2015-12-03 주식회사 녹십자 포도상구균 감염 질환의 예방 또는 치료용 조성물
WO2017010845A1 (ko) * 2015-07-15 2017-01-19 재단법인 목암생명과학연구소 포도상구균 감염 질환의 예방 또는 치료용 조성물
KR101847051B1 (ko) 2016-04-26 2018-04-09 한국외국어대학교 연구산학협력단 병원균에 대한 항생활성을 갖는 펩타이드 및 이를 포함하는 항생 펩타이드 조성물
JP7181208B2 (ja) 2016-10-21 2022-11-30 ソクプラ、サイエンシズ、エ、ジェニ、エス．イー．シー． ワクチン構築物およびブドウ球菌感染症に対するその使用
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US12397014B2 (en) 2019-02-05 2025-08-26 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
EP3736431A1 (en) 2019-05-10 2020-11-11 Mazda Motor Corporation Engine piston and method for manufacturing the same
KR20220079534A (ko) * 2019-08-27 2022-06-13 알로펙스, 인크. 항미생물 백신 조성물
US11173199B2 (en) 2019-11-13 2021-11-16 Alopexx Inc. Low contaminant compositions
US10828360B1 (en) 2020-02-04 2020-11-10 OneBioPharma, Inc. Methods for inhibiting biofilm formation

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2842049A (en) * 1954-09-22 1958-07-08 Technicolor Corp Deacetylated chitin mordant
JPS5452794A (en) 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
US4285936A (en) 1979-12-10 1981-08-25 The United States Of America As Represented By The Secretary Of The Army Method for producing a vaccine against bacterial infections caused by pseudomonas aeruginosa
JPS5686121A (en) * 1979-12-14 1981-07-13 Teijin Ltd Antitumor proten complex and its preparation
US4355023A (en) 1980-09-30 1982-10-19 The Massachusetts General Hospital Antibody fragment compositions and process
US4443549A (en) 1981-10-19 1984-04-17 Molecular Genetics, Inc. Production of monoclonal antibodies against bacterial adhesins
US4470925A (en) 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US4462334A (en) 1982-08-19 1984-07-31 Kim Ho K Solar animal structure
US4465776A (en) 1982-09-27 1984-08-14 Research Corporation Monoclonal antibodies to vitamin B6 and immunoassay method
US4652448A (en) 1982-10-07 1987-03-24 Molecular Genetics, Inc. Use of monoclonal antibodies against bacterial adhesins
US4578458A (en) 1983-03-23 1986-03-25 Brigham And Women's Hospital Mucoid exopolysaccharide vaccine against Pseudomonas aeruginosa
DK219084D0 (da) 1984-05-02 1984-05-02 Frederik Carl Peter Lindberg Antigen
JPS6191131A (ja) 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
GB8426463D0 (en) 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
NZ214503A (en) 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
FR2581877B1 (fr) 1985-05-14 1987-12-18 Louvain Universite Catholique Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
US4755381A (en) 1986-03-27 1988-07-05 Swiss Serum And Vaccine Institute Berne Klebsiella capsular polysaccharide vaccine
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4786592A (en) 1986-06-18 1988-11-22 Scripps Clinic And Research Foundation Neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin
US5589591A (en) 1986-07-03 1996-12-31 Advanced Magnetics, Inc. Endotoxin-free polysaccharides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8621910D0 (en) 1986-09-11 1986-10-15 Technology Licence Co Ltd Monoclonal antibodies
FR2619122B1 (fr) 1987-08-03 1990-03-09 Pasteur Institut Procede d'obtention de polyosides capsulaires de staphylocoques, polyosides obtenus, applications de ces polyosides et souches pour la mise en oeuvre du procede
US4859449A (en) 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
CA1340506C (en) 1987-11-24 1999-04-20 Nicholas H. Carbonetti Production of gonorrheal pi proteins and vaccines
US5204098A (en) 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
US5055455A (en) 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
FR2640628A1 (fr) 1988-12-16 1990-06-22 Commissariat Energie Atomique Oligosaccharides lies (beta)-(1 -> 6) en particulier des 2-acetamido-2-desoxy-glucoses ou - galactoses et leur preparation
AU640118B2 (en) 1988-12-19 1993-08-19 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Meningococcal class 1 outer-membrane protein vaccine
CA2039789A1 (en) 1990-04-27 1991-10-28 Samuel J. Danishefsky Calicheamicinone, derivatives and analogs thereof and methods of making the same
US5571511A (en) 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
US5763191A (en) 1990-12-12 1998-06-09 Boehringer Mannheim Gmbh Universal binding film
DE4219159A1 (de) 1992-06-11 1993-12-16 Boehringer Mannheim Gmbh Selbst assemblierende Monoschicht mit kurzkettigen Linkern
US5352670A (en) 1991-06-10 1994-10-04 Alberta Research Council Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides
DE69230037T2 (de) 1991-07-12 2000-01-05 Pfizer Inc., New York Kontinuierliche zellinie sowie impfstoff gegen geflügelinfektion mit kokkidien
ES2198405T3 (es) 1991-11-22 2004-02-01 Nabi Biopharmaceuticals Antigenos de superficie de tipo i asociados a staphylococcus epidermis.
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
AU667069B2 (en) 1991-12-06 1996-03-07 North Shore University Hospital Research Corporation Method of reducing medical device related infections
DE69329642T3 (de) 1992-03-19 2009-05-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Breitreaktive opsonische antikörper die mit gemeinsamen antigenen von staphylococcus reagieren
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
US5688516A (en) 1992-11-12 1997-11-18 Board Of Regents, The University Of Texas System Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
US5362754A (en) 1992-11-12 1994-11-08 Univ. Of Tx Md Anderson Cancer Center M-EDTA pharmaceutical preparations and uses thereof
EP0680337A4 (en) 1993-01-12 1997-07-30 Anthony George Gristina METHODS AND COMPOSITIONS FOR DIRECT APPLICATION WITH HIGH CONCENTRATION OF ANTIBODIES, PRODUCING PASSIVE IMMUNITY.
US5718694A (en) 1993-11-09 1998-02-17 The Board Of Regents Of The University Of Nebraska Inhibition of adherence of microorganisms to biomaterial surfaces by treatment with carbohydrates
US5858350A (en) 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
HU221001B1 (hu) 1994-03-17 2002-07-29 Merck Patent Gmbh. Egyláncú anti-EGFR Fv-k és anti-EGFR ellenanyagok
JPH0840932A (ja) 1994-07-29 1996-02-13 Kitasato Inst:The スタフイロコッカス属菌感染症の予防ワクチン及び治療用抗体並びにそれの製造法
EP0903346A1 (en) 1995-11-06 1999-03-24 Chugai Seiyaku Kabushiki Kaisha Sydnone imine derivatives
US5830539A (en) 1995-11-17 1998-11-03 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Methods for functionalizing and coating substrates and devices made according to the methods
JP3372551B2 (ja) 1995-11-21 2003-02-04 ノバルティス アクチエンゲゼルシャフト 多価ポリマー、その製造方法、および生物学的に活性な化合物の製造におけるその使用
US6245735B1 (en) 1996-07-29 2001-06-12 The Brigham And Women's Hospital, Inc. Methods and products for treating pseudomonas infection
US6294177B1 (en) 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
CZ106299A3 (cs) 1996-09-26 1999-08-11 Chugai Seiyaku Kabushiki Kaisha Protilátky proti proteinu příbuznému s lidským parathyroidálním hormonem
DE69835201T2 (de) 1997-04-18 2007-06-14 Novartis Ag Neoglycoproteine
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
TW586934B (en) 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US5989542A (en) 1997-08-20 1999-11-23 Brigham And Women's Hospital, Inc. Capsular polysaccharides from enterococci
IT1298539B1 (it) 1998-02-03 2000-01-12 Bracco Spa Metodo per la determinazione di infezioni da protesi
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
JP2002511259A (ja) 1998-04-09 2002-04-16 ジェンセット ５’ｅｓｔおよびコードされるヒトタンパク質
US7214487B2 (en) 1998-06-26 2007-05-08 Sunesis Pharmaceuticals, Inc. Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates
DE69938784D1 (de) 1998-07-15 2008-07-03 Brigham & Womens Hospital Polysaccharid-impfstoff gegen staphylokokken infektionen
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
EP2330192A1 (en) * 1998-08-31 2011-06-08 The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
EP1140229B1 (en) 1998-12-16 2010-10-06 Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO Acidic superabsorbent polysaccharides
CA2366152A1 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
WO2002094983A2 (en) 2001-05-16 2002-11-28 The Children's Hospital Of Philadelphia Dna-antibody complexes to enhance gene transfer
US7119172B2 (en) 2001-05-21 2006-10-10 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
WO2002094854A2 (en) 2001-05-21 2002-11-28 The Brigham And Women's Hospital, Inc. P.aeruginosa mucoid exopolysaccharide specific binding peptides
US20030113350A1 (en) 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
CN1344722A (zh) 2001-10-19 2002-04-17 北京盈富安信科技有限公司 1→6连接的氨基葡聚寡糖和糖苷及其合成和应用
AU2002351208A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
EP1455817B1 (en) * 2001-12-11 2008-12-31 Merck & Co., Inc. Staphylococcus aureus exopolysaccharide and process
EP1470146B8 (en) 2001-12-28 2007-09-12 Amgen Fremont Inc. Antibodies against the muc18 antigen
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
AU2003218456A1 (en) 2002-04-01 2003-10-20 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
WO2004043405A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
NZ561879A (en) 2003-03-07 2009-05-31 Wyeth Corp Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
ES2317043T3 (es) 2003-06-23 2009-04-16 Baxter International Inc. Proteinas portadoras para vacunas.
US9928522B2 (en) 2003-08-01 2018-03-27 Oath (Americas) Inc. Audience matching network with performance factoring and revenue allocation
ES2294535T3 (es) 2003-08-12 2008-04-01 Lipoxen Technologies Limited Derivados del acido polisialico.
PL1745075T3 (pl) 2004-04-21 2013-09-30 Brigham & Womens Hospital Inc Peptydy wiążące poli-N-acetyloglukozaminę (PNAG/DPNAG) i sposoby ich zastosowania
CA2475736A1 (en) 2004-07-23 2006-01-23 Cyrille Grandjean Vibrio cholerae lps detoxified derivatives and immunogenic compositions containing them
ES2730275T3 (es) 2004-09-22 2019-11-11 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US20060134141A1 (en) 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
US20080193481A1 (en) 2005-03-14 2008-08-14 Governors Of The University Of Alberta Synthetic Anti-Candida Albicans Oligosaccharide Based Vaccines
NZ570805A (en) 2006-03-30 2011-10-28 Glaxosmithkline Biolog Sa Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus
AR060187A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
CN102159540B (zh) 2008-07-21 2015-08-12 布赖汉姆妇女医院 与合成的β-1,6葡糖胺寡糖相关的方法和组合物
CA2786891C (en) * 2009-02-20 2017-08-01 Meisho.Co.,Ltd Immunopotentiating composition and process for producing same
WO2012099805A2 (en) 2011-01-19 2012-07-26 Ocean Nanotech, Llc Nanoparticle based immunological stimulation
ES2826000T3 (es) * 2012-05-30 2021-05-17 Brigham & Womens Hospital Inc Composiciones de polisacárido y métodos de uso
EP3608416A1 (en) 2013-01-22 2020-02-12 Imicroq, S.L. Rapid method for detection of pathogen

Also Published As

Publication number Publication date
WO2004043405A3 (en) 2004-10-21
JP5814494B2 (ja) 2015-11-17
WO2004043405A2 (en) 2004-05-27
ZA200502607B (en) 2006-07-26
KR101062525B1 (ko) 2011-09-06
AU2003295520B8 (en) 2011-05-19
NO20052828D0 (no) 2005-06-10
JP2006513166A (ja) 2006-04-20
IL167532A (en) 2014-12-31
EP1565478A2 (en) 2005-08-24
JP2013010789A (ja) 2013-01-17
CA2501077A1 (en) 2004-05-27
PL229487B1 (pl) 2018-07-31
IL263585A (en) 2019-01-31
PT1565478T (pt) 2017-11-14
NZ539153A (en) 2006-11-30
ES2648046T3 (es) 2017-12-28
JP2019089845A (ja) 2019-06-13
JP2016204388A (ja) 2016-12-08
JP6335102B2 (ja) 2018-05-30
CN100351260C (zh) 2007-11-28
AU2003295520B2 (en) 2011-04-14
PL377145A1 (pl) 2006-01-23
BRPI0316018B1 (pt) 2017-04-04
CN1708506A (zh) 2005-12-14
US20050118198A1 (en) 2005-06-02
BRPI0316018B8 (pt) 2021-05-25
CA2501077C (en) 2016-06-21
BR0316018A (pt) 2005-09-20
NO341730B1 (no) 2018-01-15
KR20050074582A (ko) 2005-07-18
US10919956B2 (en) 2021-02-16
IL209149A0 (en) 2011-01-31
AU2003295520A1 (en) 2004-06-03
NO20052828L (no) 2005-08-12
DK1565478T3 (da) 2017-11-13
JP2015042676A (ja) 2015-03-05
EP1565478B1 (en) 2017-08-02
WO2004043405A8 (en) 2004-08-05
EP1565478A4 (en) 2007-01-03

Similar Documents

Publication Publication Date Title
CA2501077C (en) Polysaccharide vaccine for staphylococcal infections
US8663654B2 (en) Polysaccharide vaccine for staphylococcal infections
AU2022201447A1 (en) Polysaccharide compositions and methods of use
AU771563C (en) Polysaccharide vaccine for staphylococcal infections
HK1079214B (en) Polysaccharide vaccine for staphylococcal infections
HK1079214A (en) Polysaccharide vaccine for staphylococcal infections
PL229287B1 (pl) Sposób wytwarzania kształtek rurowych do łączenia odcinków rur z tworzyw sztucznych
HK1121690A (en) Polysaccharide vaccine for staphylococcal infections

Legal Events

Date Code Title Description
FG Grant or registration